Literature DB >> 15528315

Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I.

Monia Draghi1, Nobuyo Yawata, Michael Gleimer, Makoto Yawata, Nicholas M Valiante, Peter Parham.   

Abstract

Natural killer (NK) cells activate quickly in response to pathogens, tumors, and allogeneic hematopoietic cell transplants. Modulating the NK cell response are clonally distributed NK cell receptors that survey cells for change in the expression of major histocompatibility complex (MHC) class I and structurally related ligands. Here the enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine staining (ICS), and short-term culture were used to quantify the response of bulk NK cell populations from human donors to HLA class I-deficient 221 cells and to 221 cells transfected with single HLA class I allotypes. NK cells in cultures containing interleukin-2 (IL-2) or IL-12 exhibited specificities of HLA class I-mediated inhibition that correlated well with those previously defined using NK cell clones in long-term culture and with the frequencies of cells expressing particular inhibitory HLA class I receptors. Culture with IL-12, but not IL-2, gave an increased frequency of cells expressing CD94: NKG2A but no change in killer immunoglobulin-like receptor (KIR) expression. For some heterozygote combinations of KIR3DL1 alleles, ICS can be used to compare the functional properties of the 2 allotypes. Thus, both the low-expressing KIR3DL1*005 and the high-expressing KIR3DL1*002 gave similar inhibitory response on challenge with an HLA-B*5801 ligand. The single-cell assays developed here should facilitate future population study and clinical analysis of human NK cell regulation by MHC class I.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528315     DOI: 10.1182/blood-2004-08-3174

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.

Authors:  Wei Wang; Amy K Erbe; Kory A Alderson; Emily Phillips; Mikayla Gallenberger; Jacek Gan; Dario Campana; Jacquelyn A Hank; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-07-08       Impact factor: 6.968

2.  Phenotypic and functional activation of hyporesponsive KIRnegNKG2Aneg human NK-cell precursors requires IL12p70 provided by Poly(I:C)-matured monocyte-derived dendritic cells.

Authors:  Shane A Curran; Emanuela Romano; Michael G Kennedy; Katharine C Hsu; James W Young
Journal:  Cancer Immunol Res       Date:  2014-07-14       Impact factor: 11.151

3.  Alterations in natural killer cell receptor profiles during HIV type 1 disease progression among chronically infected South African adults.

Authors:  Ambrose H W Wong; Katie Williams; Sharon Reddy; Douglas Wilson; Janet Giddy; Galit Alter; Musie Ghebremichael; Mary N Carrington; Thumbi Ndung'u; Bruce D Walker; Marcus Altfeld; William H Carr
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

4.  Partial break in tolerance of NKG2A-/LIR-1- single KIR+ NK cells early in the course of HLA-matched, KIR-mismatched hematopoietic cell transplantation.

Authors:  S Rathmann; C Keck; C Kreutz; N Weit; M Müller; J Timmer; S Glatzel; M Follo; M Malkovsky; M Werner; R Handgretinger; J Finke; P Fisch
Journal:  Bone Marrow Transplant       Date:  2017-05-08       Impact factor: 5.483

5.  MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response.

Authors:  Makoto Yawata; Nobuyo Yawata; Monia Draghi; Fotini Partheniou; Ann-Margaret Little; Peter Parham
Journal:  Blood       Date:  2008-06-26       Impact factor: 22.113

6.  Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.

Authors:  J R Vidal-Castiñeira; A López-Vázquez; R Díaz-Peña; R Alonso-Arias; J Martínez-Borra; R Pérez; J Fernández-Suárez; S Melón; J Prieto; L Rodrigo; C López-Larrea
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

7.  Use of natural killer cells as immunotherapy for leukaemia.

Authors:  Bartosz Grzywacz; Jeffrey S Miller; Michael R Verneris
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

Review 8.  The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).

Authors:  Bree Foley; Martin Felices; Frank Cichocki; Sarah Cooley; Michael R Verneris; Jeffrey S Miller
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

9.  Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1.

Authors:  Bharati Sanjanwala; Monia Draghi; Paul J Norman; Lisbeth A Guethlein; Peter Parham
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

10.  KIR-HLA profiling shows presence of higher frequencies of strong inhibitory KIR-ligands among prognostically poor risk AML patients.

Authors:  Meixin Shen; Yeh-Ching Linn; Ee-Chee Ren
Journal:  Immunogenetics       Date:  2015-12-09       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.